| 李华燕 李斌 黄建斌 陈利民.基于EPOR、HMGA2表达变化探讨康莱特防治进展期胃癌的临床研究[J].实用中西医结合临床,2015,15(12):5-8 |
| 基于EPOR、HMGA2表达变化探讨康莱特防治进展期胃癌的临床研究 |
| Clinical Study of Kanglaite Injection in Treating Advanced Gastric Cancer Based on the Changed-expression of EPOR and HMGA2 |
| |
| DOI： |
| 中文关键词: 胃癌 促红细胞生成素受体 高迁移率族蛋白A2 康莱特 |
| 英文关键词: Gastric cancer Eerythropoietin receptor High mobility group protein A2 Kanglaite injection |
| 基金项目: |
|
| 摘要点击次数: 487 |
| 全文下载次数: 350 |
| 中文摘要: |
| 目的：观察胃癌患者治疗前后Karnofsky评分以及EPOR、HMGA2表达变化，探讨康莱特注射液防治胃癌的机制研究。方法：48例符合诊断标准、纳入标准、排除标准的胃癌患者按就诊顺序1∶1分为对照组与治疗组。对照组给予化疗药物治疗，治疗组给予康莱特注射液联合化疗药物治疗，两组均治疗2个疗程。应用Karnofsky评分记录两组患者治疗前后生活质量积分变化，应用免疫组化技术检测两组治疗前后EPOR、HMGA2表达变化。结果：全部病例完成临床观察，治疗组完全缓解0例、部分缓解8例、稳定10例、进展6例，总有效率为75.0%；对照组完全缓解0例、部分缓解7例、稳定8例、进展9例，总有效率为62.5%：两组总有效率比较差异有统计学意义（P＜0.05）。治疗前，两组患者Karnofsky评分比较差异无统计学意义（P＞0.05）。治疗后治疗组Karnofsky评分高于对照组，且治疗8周后两组比较差异具有统计学意义（P＜0.05）。治疗组EPOR、HMGA2表达水平呈下降趋势，较治疗前差异有统计学意义。对照组EPOR、HMGA2表达水平较治疗前无明显变化。结论：康莱特注射液可能通过调控EPOR、HMGA2表达水平，提高患者生存质量，有效缓解其临床症状。 |
| 英文摘要: |
| Objective: To explore the mechanism of Kanglaite injection by the observation of the changed-expression of the EPOR and HMGA2 and the Karnofsky score in the advanced gastric cancer patients before and after treatment. Methods: 48 Patients meet the diagnostic criteria, inclusion criteria and exclusion criteria of advanced gastric cancer were divided into the control group and the treatment group according to the order of treatment. The control group was given chemotherapy drug, and the treatment group was given Kanglaite injection combined with chemotherapy drug. The life quality score was recored according to Karnofsky score before and after treatment. The expression of HMGA2 and EPOR were detected by immunohistochemical technique. Results: All the patients were completed the clinical observation, the total efficiency of the treatment group was 75.0%, the total efficiency of the control group was 62.5%, there was a statistical significant between the two groups (P＜0.05). Before treatment, there was no significant difference between the two group in Karnofsky scores (P＞0.05). But, the Karnofsky score of the treatment group was higher than that of the control group after treatment, and there was statistical significance between the two groups after second courses of treatment (P＜0.05). Before the treatment, the expression of HMGA2 and EPOR were in the increment. Then the expression of HMGA2 and EPOR were on the decline after the treatment (P＜0.05). The expression of HMGA2 and EPOR in the control group had no significant change (P＞0.05). Conclusion: Kanglaite injection can effectively remissive the clinical symptoms of gastric cancer and improve the life quality by regulating the expression of EPOR and HMGA2. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
